These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38045985)

  • 1. Cost-effectiveness of treatment in adults with blood pressure of 130-139/80-89 mmHg and high cardiovascular risk in China: a modelling study.
    Li J; Zhao D; Cai J; Chen S; Wu S; Qi Y
    Lancet Reg Health West Pac; 2024 Jan; 42():100962. PubMed ID: 38045985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
    Gu D; He J; Coxson PG; Rasmussen PW; Huang C; Thanataveerat A; Tzong KY; Xiong J; Wang M; Zhao D; Goldman L; Moran AE
    PLoS Med; 2015 Aug; 12(8):e1001860. PubMed ID: 26241895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study.
    Li C; Chen K; Cornelius V; Tomeny E; Wang Y; Yang X; Yuan X; Qin R; Yu D; Wu Z; Wang D; Chen T
    PLoS Med; 2021 Mar; 18(3):e1003515. PubMed ID: 33661907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.
    Palmer MJ; Barnard S; Perel P; Free C
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012675. PubMed ID: 29932455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of initiation of antihypertensive therapy strategies for primary prevention of cardiovascular diseases in Chinese population: A decision-analytic Markov modelling study].
    Zhou T; Liu Q; Zhang M; Liu X; Kang J; Shen P; Lin H; Tang X; Gao P
    Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Jun; 56(3):441-447. PubMed ID: 38864129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [No Abstract]   [Full Text] [Related]  

  • 7. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands.
    Stevanović J; O'Prinsen AC; Verheggen BG; Schuiling-Veninga N; Postma MJ; Pechlivanoglou P
    Clin Ther; 2014 Mar; 36(3):368-84.e5. PubMed ID: 24534654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost and cost-effectiveness of a school-based education program to reduce salt intake in children and their families in China.
    Li X; Jan S; Yan LL; Hayes A; Chu Y; Wang H; Feng X; Niu W; He FJ; Ma J; Han Y; MacGregor GA; Wu Y
    PLoS One; 2017; 12(9):e0183033. PubMed ID: 28902880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness.
    Hageman SHJ; Dorresteijn JAN; Bots ML; Asselbergs FW; Westerink J; van der Meulen MP; Mosterd A; Visseren FLJ; ; Asselbergs FW; Nathoe HM; de Borst GJ; Bots ML; Geerlings MI; Emmelot MH; de Jong PA; Leiner T; Lely AT; van der Kaaij NP; Kappelle LJ; Ruigrok YM; Verhaar MC; Visseren FLJ; Westerink J
    Eur J Prev Cardiol; 2022 Mar; 29(4):635-644. PubMed ID: 34009323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
    Moise N; Huang C; Rodgers A; Kohli-Lynch CN; Tzong KY; Coxson PG; Bibbins-Domingo K; Goldman L; Moran AE
    Hypertension; 2016 Jul; 68(1):88-96. PubMed ID: 27181996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of drug treatment for young and middle-aged stage 1 hypertensive patients with high risk.
    Zhou YF; Deng H; Wang GD; Chen S; Xing A; Wang Y; Zhao H; Gao J; Wu S
    J Glob Health; 2023 Nov; 13():04147. PubMed ID: 37997845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study.
    Lin JK; Moran AE; Bibbins-Domingo K; Falase B; Pedroza Tobias A; Mandke CN; Kazi DS
    Lancet Glob Health; 2019 Oct; 7(10):e1346-e1358. PubMed ID: 31477544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effectiveness of different screening strategies for primary prevention of cardiovascular diseases in a rural northern Chinese population].
    Si YQ; Tang X; Zhang DD; He L; Cao Y; Wang JW; Li N; Liu JJ; Gao P; Hu YH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Jun; 50(3):443-449. PubMed ID: 29930411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
    Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
    Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of Intensive vs Standard Blood Pressure Control Among Older Patients With Hypertension.
    Liao CT; Toh HS; Sun L; Yang CT; Hu A; Wei D; Melgarejo J; Zhang ZY
    JAMA Netw Open; 2023 Feb; 6(2):e230708. PubMed ID: 36848091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.
    Mozaffarian D; Liu J; Sy S; Huang Y; Rehm C; Lee Y; Wilde P; Abrahams-Gessel S; de Souza Veiga Jardim T; Gaziano T; Micha R
    PLoS Med; 2018 Oct; 15(10):e1002661. PubMed ID: 30278053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg.
    Tajeu GS; Booth JN; Colantonio LD; Gottesman RF; Howard G; Lackland DT; O'Brien EC; Oparil S; Ravenell J; Safford MM; Seals SR; Shimbo D; Shea S; Spruill TM; Tanner RM; Muntner P
    Circulation; 2017 Aug; 136(9):798-812. PubMed ID: 28634217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Initiating Pharmacological Treatment in Stage One Hypertension Based on 10-Year Cardiovascular Disease Risk: A Markov Modeling Study.
    Constanti M; Floyd CN; Glover M; Boffa R; Wierzbicki AS; McManus RJ
    Hypertension; 2021 Feb; 77(2):682-691. PubMed ID: 33342242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.